| Psoriasis vulgaris
Siliq vs Lexette
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Siliq vs Lexette with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLexette has a higher rate of injection site reactions vs Siliq based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lexette but not Siliq, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Siliq
Lexette
At A Glance
Subcutaneous
Every 2 weeks
IL-17RA antagonist
Topical
Twice daily
Corticosteroid
Indications
- Psoriasis vulgaris
- Psoriasis vulgaris
Dosing
Psoriasis vulgaris 210 mg subcutaneously at Weeks 0, 1, and 2 followed by 210 mg every 2 weeks.
Psoriasis vulgaris Apply a thin uniform film to affected skin twice daily for up to 2 weeks; shake can and invert before use; do not exceed 50 g per week; avoid face, groin, and axillae; not for use with occlusive dressings unless directed by physician.
Contraindications
- Crohn's disease
- Clinically significant hypersensitivity to brodalumab or to any of the excipients
—
Adverse Reactions
Most common (>=1%) Arthralgia (4.7%), headache (4.3%), fatigue (2.6%), diarrhea (2.2%), oropharyngeal pain (2.1%), nausea (1.9%), myalgia (1.7%), injection site reactions (1.5%), influenza (1.3%), neutropenia (1.0%), tinea infections (1.0%).
Serious Suicidal ideation and behavior (0.37 per 100 subject-years), infections including fungal infections, neutropenia grade >=3.
Postmarketing Hypersensitivity reactions, anaphylaxis including anaphylactic shock, pruritus, rashes, eczema, urticaria, dermatitis, eczematous eruptions (atopic dermatitis-like eruptions).
Most common (>=1%) Application site burning/stinging, application site pain, headache
Postmarketing Folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, irritation, striae, miliaria
Pharmacology
Brodalumab is a human monoclonal IgG2 antibody that selectively binds to IL-17RA and inhibits its interactions with IL-17 family cytokines (IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer, IL-25), thereby blocking IL-17 cytokine-induced pro-inflammatory responses.
Topical super-high potency corticosteroid; halobetasol propionate plays a role in cellular signaling, immune function, inflammation, and protein regulation, though its precise mechanism of action in plaque psoriasis is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Siliq
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Lexette
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Siliq
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Lexette
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Siliq
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Lexette
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$50/momo
Siliq Solutions Instant Savings Program - Non-covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Lexette.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LexetteView full Lexette profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.